# hcde-410-final

This project is mainly meant to approach the question of medicalized inequality, specifically in the realm of drug prices and their gendered and racialized implications. It intends to take a critical approach in considering how the monitization of drugs is produced and related to social and structural situations.

Compiled links and descriptions:

(1) Research links for HIV datasets:

https://www.cms.gov/files/document/medicare-part-d-drug-spending-methodology-2019.pdf
https://www.va.gov/opal/nac/fss/pharmPrices.asp
https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/cost-considerations-and-antiretroviral-therapy

All three of these sites were primarily used for research regarding HIV medication costs in the United States. The third link in particular was used to create data visualizations which can be found in file.

(2) Background research and expansion research links:

https://www.amfar.org/cost-of-hiv-rising/#:~:text=A%20new%20study%20reports%20a,%2425%2C000%20to%20%2435%2C000%20in%202012.
Discussing the relevance and important context to HIV and ART treatment in the United States and reasons why costs are changing. Gives context and necessary information to understand why this topic is relevant, the scope and impacts of these changes, and the degrees to which this is affected by legal, social, and economic incentives.

https://www.nytimes.com/2018/09/18/opinion/pricing-hiv-drugs-america.html
This article highlights a comparative difference in HIV drug treatment in Africa being around 75 𝑎𝑦𝑒𝑎𝑟𝑎𝑠𝑜𝑝𝑝𝑜𝑠𝑒𝑑𝑡𝑜 39,000 a year in the United States. This doesn't consider the various income differences, but in all this shows the huge cost differences in the regions.

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2759735
This article contains data and information that can be used to look at the historical changes in HIV costs and access in the United States specifically in the past decade or two. I intend to use the information and data from this to make insights regarding ART and HIV treatment accessibility in the United States while considering how generic options along with regulatory changes have impacted these prices.